Last Price$523.6(1.0%)
Market Cap$201.0B
0.1%
Peers median - 1.5%
16.9%
Peers median - 18.2%
63.1%
Peers median - 28.2%
8.3%
Peers median - 11.7%
Competing with TMO
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$201.0B | 6.5 | $602.4 15.0% undervalued | (9.7%) | $42.9B | $7,267.0M | 0.1% | 16.9% | 41.5% | 8.3% | 63.1% | |
$151.3B | 6.1 | $167.0 18.8% overvalued | (19.4%) | $23.9B | $5,296.0M | (0.1%) | 22.2% | 59.5% | 5.9% | 32.3% | |
$36.5B | 7.4 | $103.7 17.9% overvalued | (11.0%) | $6,533.0M | $1,409.0M | (3.0%) | 21.6% | 65.9% | 14.7% | 55.8% | |
$36.1B | 7.2 | $219.3 49.8% overvalued | (23.5%) | $3,897.5M | $798.1M | 6.5% | 20.5% | 61.1% | 49.4% | 6.3% | |
$33.7B | 6.1 | $301.3 63.0% undervalued | (26.5%) | $15.4B | $2,114.0M | 2.5% | 13.7% | 31.4% | 8.8% | 21.7% | |
$27.1B | 7.0 | $869.6 31.5% overvalued | (1.4%) | $3,872.4M | $864.4M | 2.2% | 22.3% | 59.1% | 49.8% | (1,587.1%) | |
$22.2B | 6.5 | $236.1 36.5% overvalued | 7.2% | $2,958.4M | $619.6M | 0.1% | 20.9% | 58.2% | 19.4% | 0.0% | |
$21.2B | 6.1 | $621.0 144.4% undervalued | 17.1% | $13.0B | $1,095.9M | 0.8% | 8.4% | 26.9% | 6.0% | 24.1% | |
$19.6B | 6.0 | $369.8 109.0% undervalued | 44.2% | $9,872.0M | $909.0M | 6.7% | 9.2% | 32.4% | 8.8% | 102.2% | |
$18.5B | 6.0 | $70.9 50.4% overvalued | 58.6% | $1,532.0M | ($33.2M) | 54.9% | (2.2%) | 57.7% | (44.9%) | 54.2% | |
$13.9B | 6.2 | $147.2 74.8% undervalued | (37.1%) | $4,372.0M | $696.0M | (2.9%) | 15.9% | 65.4% | 34.6% | 93.8% |
Compare TMO Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
Thermo Fisher Scientific Inc.TMO
5.3x
(4.6%)
(12.4%)
14.0%
Median Peer Set
6.4x
(0.3%)
(2.0%)
12.8%
Agilent Technologies, Inc.A
5.9x
(4.7%)
5.0%
19.8%
Quest Diagnostics IncorporatedDGX
2.6x
(6.4%)
(6.5%)
9.2%
Danaher CorporationDHR
6.9x
(0.1%)
(17.9%)
16.3%
IDEXX Laboratories, Inc.IDXX
9.2x
8.7%
25.2%
23.1%
Illumina, Inc.ILMN
3.5x
(2.9%)
4.6%
(28.0%)
IQVIA Holdings Inc.IQV
2.2x
2.8%
2.4%
8.9%
Laboratory Corporation of America HoldingsLH
N/A
(18.3%)
(65.8%)
3.4%
Mettler-Toledo International Inc.MTD
7.5x
2.2%
12.7%
22.3%
Natera, Inc.NTRA
11.8x
32.0%
(32.1%)
(40.2%)
Waters CorporationWAT
7.4x
(0.5%)
(7.9%)
21.7%
Compare TMO Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does Thermo Fisher Scientific Inc. (TMO) revenue growth compare to peers and the industry?
Thermo Fisher Scientific Inc. (TMO) revenue growth is 0.1%, compared to the peers' median of 1.5%.
2. How does Thermo Fisher Scientific Inc. (TMO) Free Cash Flow (FCF) margin compare to peers and the industry?
Thermo Fisher Scientific Inc. (TMO) FCF margin is 16.9%, compared to the peers' median of 18.2%.
3. How does Thermo Fisher Scientific Inc. (TMO) Total Debt to Equity ratio compare to peers and the industry?
Thermo Fisher Scientific Inc. (TMO) Total Debt to Equity ratio is 63.1%, compared to the peers' median of 28.2%.
4. How does Thermo Fisher Scientific Inc. (TMO) ROIC (Return on Invested Capital) compare to peers and the industry?
Thermo Fisher Scientific Inc. (TMO) ROIC is 8.3%, compared to the peers' median of 11.7%.